Cryoport, Inc. CYRX
We take great care to ensure that the data presented and summarized in this overview for Cryoport, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYRX
View all-
Cadian Capital Management, LP New York, NY4.93MShares$31.6 Million2.22% of portfolio
-
Morgan Stanley New York, NY4.66MShares$29.9 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD4.46MShares$28.6 Million0.82% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.14MShares$26.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.42MShares$21.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.73MShares$17.5 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY2.57MShares$16.5 Million0.1% of portfolio
-
Thematics Asset Management Paris, I01.71MShares$10.9 Million0.59% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.4MShares$8.96 Million0.0% of portfolio
-
Assenagon Asset Management S.A.1.33MShares$8.55 Million0.02% of portfolio
Latest Institutional Activity in CYRX
Top Purchases
Top Sells
About CYRX
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Insider Transactions at CYRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 10
2025
|
Robert Stefanovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,256
-0.68%
|
$5,024
$4.88 P/Share
|
Mar 10
2025
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
4,173
-0.56%
|
$16,692
$4.88 P/Share
|
Mar 10
2025
|
Mark W Sawicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,583
-1.98%
|
$6,332
$4.88 P/Share
|
Mar 09
2025
|
Robert Stefanovich Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+1.43%
|
-
|
Mar 09
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,250
+1.1%
|
-
|
Mar 09
2025
|
Mark W Sawicki Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+3.22%
|
-
|
Dec 11
2024
|
Robert Stefanovich Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
53,334
+22.7%
|
$213,336
$4.8 P/Share
|
Dec 02
2024
|
Ramkumar Mandalam Director |
SELL
Open market or private sale
|
Direct |
7,369
-11.02%
|
$51,583
$7.46 P/Share
|
Dec 02
2024
|
Ramkumar Mandalam Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,834
+13.94%
|
$43,336
$4.8 P/Share
|
Nov 22
2024
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
22,817
-3.01%
|
$136,902
$6.47 P/Share
|
Nov 22
2024
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,862
+3.42%
|
$107,448
$4.8 P/Share
|
Nov 21
2024
|
Robert J Hariri Director |
SELL
Open market or private sale
|
Direct |
2,500
-10.84%
|
$15,000
$6.48 P/Share
|
Nov 21
2024
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
50,000
-6.39%
|
$300,000
$6.51 P/Share
|
Nov 21
2024
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,150
+7.03%
|
$236,600
$4.8 P/Share
|
Nov 20
2024
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
50,000
-6.47%
|
$300,000
$6.65 P/Share
|
Nov 20
2024
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+7.21%
|
$240,000
$4.8 P/Share
|
Nov 19
2024
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
50,000
-6.56%
|
$300,000
$6.78 P/Share
|
Nov 19
2024
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,440
+7.34%
|
$241,760
$4.8 P/Share
|
Nov 18
2024
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
50,000
-6.65%
|
$300,000
$6.73 P/Share
|
Nov 18
2024
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,215
+7.41%
|
$240,860
$4.8 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 64.2K shares |
---|---|
Exercise of conversion of derivative security | 349K shares |
Open market or private sale | 263K shares |
---|